Recent

% | $
Quotes you view appear here for quick access.

Pharmacyclics, Inc. Message Board

  • crossmebaby123 crossmebaby123 Dec 9, 2013 8:40 AM Flag

    PCYC management where is our news from ASH?????

    where the heck is it

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Key dates .Dec 9 Dec, 10 read,Ibrutinib in combination with bendamustine and rituximab is active and tolerable in patients with relapsed/refractory CLL/SLL: final results of a phase 1b study. (Abstract 525)
      Oral session: CLL: Therapy, excluding Transplantation: Chemoimmunotherapy Clinical Trials. Monday, December 9 at 3:15 pm CST in Ernest N. Morial Convention Center, 220-222

      Combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP): updated results from a phase 1b study in treatment-naïve patients with CD20-positive B-cell non-Hodgkin’s lymphoma (NHL). (Abstract 852)
      Oral session: Lymphoma: Therapy with Biological Agents, Excluding Pre-Clinical Models: Aggressive Lymphomas. Tuesday, December 10 at 8:45 am CST in Ernest N. Morial Convention Center, La Nouvelle Ballroom AB The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) monotherapy demonstrates long-term safety and durability of response in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) patients in an open-label extension study. (Abstract 4163)
      Poster session: CLL: Therapy, excluding Transplantation: Poster I. Monday, December 9 at 6:00-8:00 pm CST in Ernest N. Morial Convention Center, Hall E Less

      Sentiment: Strong Buy

    • Later today, this evening, and more tomorrow.

    • What is ASH?

 
PCYC
257.100.00(0.00%)Apr 23 3:59 PMEDT